Imunofan ampoules 0,005% 1ml №5

Mechanism of action

Imunofan - an immunomodulating agent. It has immunoregulatory, detoxification, hepatoprotective effects and causes inactivation of free radical and peroxide compounds. Pharmacological action is based on the achievement of three main effects: correction of the immune system, restoring the balance of the oxidative-antioxidant reaction of the body and inhibition of multidrug resistance mediated by proteins of the transmembrane cell transport pump.

The action of the drug begins to develop within 2-3 hours (fast phase) and lasts up to 4 months (medium and slow phases).

During the fast phase (duration - up to 2-3 days), the detoxification effect is manifested primarily - the antioxidant protection of the body is enhanced by stimulating the production of ceruloplasmin, lactoferrin, catalase activity; the drug normalizes lipid peroxidation, inhibits the breakdown of cell membrane phospholipids and the synthesis of arachidonic acid, followed by a decrease in blood cholesterol and production of inflammatory mediators. In case of toxic and infectious liver damage, the drug prevents cytolysis, reduces transaminase activity and serum bilirubin level.

During the middle phase (starts in 2-3 days, duration - up to 7-10 days), there is an increase in the reactions of phagocytosis and the death of intracellular bacteria and viruses.

During the slow phase (it starts developing at 7-10 days, duration up to 4 months), immunoregulatory action of Imunofan is manifested - restoration of impaired indicators of cellular and humoral immunity. During this period, normalization of the immunoregulatory index is observed, an increase in the production of specific antibodies is noted. The effect of Imunofan on the production of specific antiviral and antibacterial antibodies is equivalent to the action of some therapeutic vaccines. Unlike the latter, the drug has no significant effect on the production of reagin antibodies of the IgE class and does not enhance the immediate-type hypersensitivity reaction; Imunofan stimulates the formation of IgA in its congenital insufficiency.

Imunofan effectively suppresses the multidrug resistance of tumor cells and increases their sensitivity to the action of cytotoxic drugs.

Indications and usage

Applied in adults and children older than two years for the prevention and treatment of immunodeficiency and toxic conditions, chronic inflammatory diseases of various etiologies. In adults, as an adjuvant for vaccination against bacterial and viral infections.

Contraindications

Hypersensitivity, pregnancy complicated by Rh-conflict, children under 2 years of age.

Dosage and administration

The solution for injection prescribed subcutaneously or intramuscularly, courses. Single and daily dose - 50 mg.

Duration and treatment regimen is selected individually depending on the disease.

Adverse reactions

Individual intolerance is possible.

As a result of the activation of phagocytosis, a short-term exacerbation of the foci of chronic inflammation, supported by the persistence of viral or bacterial antigens, is possible.

Storage conditions

In a dry, protected from light, out of reach of children at a temperature of from 2 to 10 ° C.

Imunofan